When Veridian Genomics closed at a $4.2B valuation, the wire copy wrote itself: a precision-medicine darling finally cashes the chip it had been holding since 2015. The reality on the cap table is messier.
Crossover investors who anchored the 2021 and 2022 rounds were marked at significantly higher implied valuations. Liquidation preferences kicked in before common holders saw a number worth celebrating.
What this exit really tells us is that Series D and beyond in AI-bio is now a multi-headed beast — and founders who optimize for headline numbers without modeling preference stacks are signing checks they don't know they're writing.
The next wave of AI-diagnostics M&A will be priced off this one. Expect tighter ratchets, more participating preferred, and boards that are far less generous about secondaries.
